Literature DB >> 8704235

Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines.

R M Weber-Nordt1, C Egen, J Wehinger, W Ludwig, V Gouilleux-Gruart, R Mertelsmann, J Finke.   

Abstract

Although various molecular mechanisms of STAT protein (signal transducers and activators of transcription) activation have been identified, little is known about the functional role of STAT-dependent transcriptional activation. Herein we report the constitutive nuclear localization, phosphorylation, and DNA-binding activity of STAT proteins in leukemia cells and lymphoma cell lines. With the use of oligonucleotide probes derived from the Fc gamma RI promoter, the beta-casein promoter and a STAT-binding element in the promoter of the Bci-2 gene constitutive activation of STAT proteins was detected in untreated acute T- and C/B-leukemia cells (3 of 5 and 12 of 19 patients, respectively). Supershift analyses using Stats 1-6 specific antisera showed the constitutive DNA binding activity of Stat5 in these cells. Confocal microscopy revealed the nuclear localization of Stat5 and Western blot analyses showed tyrosine phosphorylation of Stat5 in nuclear extracts of acute leukemia cells. In contrast, peripheral blood mononuclear cells did not display constitutive STAT-DNA interaction. Further studies were performed on freshly isolated acute myeloid leukemia cells as well as on cell line derived K562, lymphoblastoid cells (LCL), and Burkitt's lymphoma cells (BL). Fluorescence microscopy, gelshift, and supershift experiments showed the nuclear localization and constitutive DNA-binding activity of Stat5 in K562 cells. Stat1 and Stat3 were constitutively activated in freshly isolated AML cells (10 of 14 patients) and in Epstein Barr virus-positive or interleukin-10 expressing permanent LCL and BL cells. Thus, these data indicate a differential pattern of STAT protein activation in lymphoid or myeloid leukemia and in lymphoma cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8704235

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  76 in total

1.  The Epstein-Barr virus latency BamHI-Q promoter is positively regulated by STATs and Zta interference with JAK/STAT activation leads to loss of BamHI-Q promoter activity.

Authors:  H Chen; J M Lee; Y Wang; D P Huang; R F Ambinder; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

2.  Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors.

Authors:  H Chen; J M Lee; Y Zong; M Borowitz; M H Ng; R F Ambinder; S D Hayward
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

3.  Novel iodoacetamido benzoheterocyclic derivatives with potent antileukemic activity are inhibitors of STAT5 phosphorylation.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Filippo Prencipe; Carlota Lopez-Cara; Riccardo Rondanin; Daniele Simoni; Ernest Hamel; Stefania Grimaudo; Rosaria Maria Pipitone; Maria Meli; Manlio Tolomeo
Journal:  Eur J Med Chem       Date:  2015-11-27       Impact factor: 6.514

Review 4.  The role of chalcones in suppression of NF-κB-mediated inflammation and cancer.

Authors:  Vivek R Yadav; Sahdeo Prasad; Bokyung Sung; Bharat B Aggarwal
Journal:  Int Immunopharmacol       Date:  2010-12-22       Impact factor: 4.932

Review 5.  Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.

Authors:  Tariq I Mughal; Saulius Girnius; Steven T Rosen; Shaji Kumar; Adrian Wiestner; Omar Abdel-Wahab; Jean-Jacques Kiladjian; Wyndham H Wilson; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2014-02-17

6.  Dysregulation of janus kinases and signal transducers and activators of transcription in cancer.

Authors:  Ana P Costa-Pereira; Nair A Bonito; Michael J Seckl
Journal:  Am J Cancer Res       Date:  2011-06-22       Impact factor: 6.166

Review 7.  Targeting signal transducer and activator of transcription signaling pathway in leukemias.

Authors:  Mustafa Benekli; Heinz Baumann; Meir Wetzler
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

8.  Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth.

Authors:  Paul L Leong; Genevieve A Andrews; Daniel E Johnson; Kevin F Dyer; Sichuan Xi; Jeffrey C Mai; Paul D Robbins; Seshu Gadiparthi; Nancy A Burke; Simon F Watkins; Jennifer Rubin Grandis
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-14       Impact factor: 11.205

9.  Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease regions.

Authors:  Therese Högfeldt; Crystal Jaing; Kevin Mc Loughlin; James Thissen; Shea Gardner; Abeer A Bahnassy; Baback Gharizadeh; Joachim Lundahl; Anders Österborg; Anna Porwit; Abdel-Rahman N Zekri; Hussein M Khaled; Håkan Mellstedt; Ali Moshfegh
Journal:  Oncol Lett       Date:  2016-08-16       Impact factor: 2.967

10.  STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease.

Authors:  Geqiang Li; Kristy L Miskimen; Zhengqi Wang; Xiu Yan Xie; Jennifer Brenzovich; John J Ryan; William Tse; Richard Moriggl; Kevin D Bunting
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.